Abstract library

14 results for "DeRoose".
#2947 Al18F-NOTA-Octreotide PET Imaging of the Somatostatin Receptor: First Comparison with 68Ga-DOTATATE in Neuroendocrine Tumor Patients
Introduction: Practical and economic challenges limit the widespread use of 68Ga-labeled somatostatin analog (SSA) PET, the current standard for somatostatin receptor imaging. A promising 18F-labeled SSA, Al18F-NOTA-octreotide (Al18F-OC), has recently been introduced.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Elin Pauwels
#3079 Novel Symptoms and Therapy of Multiple Endocrine Neoplasia Type 1
Introduction: MEN1 is a rare autosomal inherited disease with hallmark of hyperparathyroidism, duodenopancreatic NENs and pituitary tumor.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: Jian-An Bai
Authors: Bai J A, Tang Q, ...
#110 Slug represents an important regulator of E-cadherin expression in neuroendocrine tumor cells of the pancreas
Introduction: Neuroendocrine tumors of the pancreas form an inhomogenous group of epithelial neoplasms. They differ from other types of pancreatic cancers by showing an extended survival of patients, which is due to a mostly slow proliferation rate of the tumor. However, some of these neuroendocrine tumors are characterized by an early onset of metastases, which cannot be predicted by any available method. The epithelial to mesenchymal transition (EMT) represents a central part of cell migration and metastasis. During EMT, cells loosen their cellular contacts, leave the tissue, and become migrating single cells. One of the integral compounds of cell adhesion represents the E-cadherin adhesion module, which contains mostly E-cadherin and several catenins. A loss of this adhesion module is associated with tumor progression, migration and metastasis in many types of cancer.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Dr Alexander König
#153 Antibody formation against somatostatin analogues with altered biodistribution and dosimetry: a case with implications for PRRT
Introduction: Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors (NETs) has emerged as a powerful palliative therapy. I.v. administration of radiolabeled (e.g. Yttrium-90) somatostatin analogues (SA) results in high-dose local irradiation of all tumor sites. The radiolabelled SA accumulates in the tumors through receptor-mediated internalization depending on the expression of somatostatin receptors and the pharmacokinetics of the radiolabelled SA.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Sofie Van Binnebeek
#335 Dosimetry with 111In-octreotide and Coinfusion of Amino Acids in the Prediction of Nephrotoxicity in Neuroendocrine Tumors after PRRT with 90Y-DOTATOC
Introduction: Kidneys are the critical organs in PRRT. A dosimetry protocol was implemented in an ongoing study to estimate the biological effective dose (BED) on the kidneys after 90Y-DOTATOC therapy.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr. Sofie M.D.A. Van Binnebeek
#1067 Gemox or Alkylating Agents in Neuroendocrine Tumors? The Help of O6-Methylguanine-DNA Methyltransferase (MGMT) Status?
Introduction: Alkylating agents are the backbone chemotherapy in neuroendocrine tumors (NET). However, gemcitabine associated to oxaliplatine (gemox) has showed interesting activity in a small study.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Medical treatment - Chemotherapy
Presenting Author: Anne-Sophie Dussol
#1105 Pre-PRRT Uptake on 68Ga-DOTATOC Predicts Good Prognosis in Neuroendocrine Tumors Patients
Introduction: There is a growing need to identify PRRT-responders on an early time point during therapy.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Sofie Van Binnebeek
Keywords: PET, response, PRRT
#1331 The Symptoms Experienced by Small Bowel and Pancreatic NET Patients Prior to Diagnosis Do Not Meet the Criteria for a Functional Diarrhoea (IBS-D) Diagnosis
Introduction: Patients with neuroendocrine tumours (NETs) complain of symptoms that may be mistaken for irritable bowel syndrome (IBS). There is no clear data if these symptoms overlap with those of IBS or if differentiating symptoms co-exist.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Dr Ron Basuroy
#1423 Multidisciplinary Management and Patient Flow in Neuroendocrine Tumors (NET): Consensus of a Tertiary Hospital
Introduction: Currently, there has been an improvement in diagnostic procedures and treatments of NET. Therefore, an effective teamwork is needed to choose the best approach for patients.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: PhD Paula Jimenez-Fonseca
#1591 Patient-Reported Preferences in Treatments Approved in Neuroendocrine Tumors: A National Survey from the French Group of Endocrine Tumors
Introduction: Patients with advanced neuroendocrine tumors (NETs) benefit from an increasing number of treatments. The patient’s preference could help physicians to choose among these options
Conference: 14th Annual ENETS conference 2017 (2017)
Category: ...none of the above
Presenting Author: Dr Arnaud Plante
Authors: Plante A, Baudin E, Do Cao C, Hentic O, ...